Search

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

Chairs and members

Chair (2024–2027 term)Igor Aurer (education and scientific meetings co-lead) – University Hospital Centre Zagreb, University of Zagreb and KroHem, Croatia

Co-chair (2024–2027 term)Martin Dreyling (guidelines lead) – University Hospital Grosshadern, Ludwig Maximilian University and GLA, Germany

SWG Executive Board members (2024–2027 term)
Kim Linton (scientific secretary) –…

Read more

EHA - Access to Medicine

By reporting the unavailability of hematology medicine you are strengthening our efforts to improve patients' access to medicine across Europe. REPORT NOW

Read more

EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias

Dates: April 25-26, 2025
Location: Berlin, Germany
Chairs: K Döhner, P Vyas, and MT Voso
Collaborating SWG: EHA Specialized Working Group on Acute Myeloid Leukemia

Registration is now open

OverviewThe EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias (sAML) will focus…

Read more

Past

EHA has organized a congress since 1994 and annually since 1998. On this page, you will find an overview of the previous congresses, locations and dates.

Read more